Dr. David Burkhart is the Chief Operating Officer and Co-Founder of Inimmune Corp and is also the Associate Director of the Center for Translational Medicine at the University of Montana. Both entities are leading vaccine adjuvant discovery and development groups bringing new adjuvants into human clinical trials.
Dr. Burkhart was an Investigator with GlaxoSmithKline Vaccines for 8 years leading the formulation team working in vaccine adjuvant R&D and immunotherapeutics space. Prior to his work with GSK, Dr. Burkhart was a Senior Scientist with the CDMO Hollister-Stier labs in Spokane, Washington for two years where he gained invaluable experience in cGMP manufacturing. He has over 17 years of experience in the biotechnology and pharmaceutical industries with experience in project management, leadership, business development, and licensing with over 20 years experience in medicinal and analytical chemistry, formulation and drug delivery. He has numerous papers and patents published in the vaccine adjuvant R&D field. David earned his Ph.D. in organic chemistry in 2002 from the University of Idaho and conducted targeted drug delivery research in oncology as a postdoctoral scientist at the University of Colorado, Boulder until 2005.